FAM86C1P

Across TCGA pan-cancer cohorts, FAM86C1P Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM86C1P data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FAM86C1P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM86C1P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, HNSC, and BRCA are the cancer types where FAM86C1P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
HNSC	OS	Median	All	0.138	0.710	.001	24	view →
BRCA	DFS	Median	All	0.140	1.000	.001	20	view →
UCEC	DFS	Median	All	1.000	0.636	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM86C1P–STAD (OS)

Open the STAD breakdown →